At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 2,272 enrolled
Drug / intervention
Placebo Arm +2 moredrug
Likely dose
Placebo Arm 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
EDUCATE: a Prospective, Multi-center Study Designed to Collect Real-world Safety and Clinical Outcomes in Subjects Receiving One or More Endeavor Zotarolimus-Eluting Stents and Either Clopidogrel and Aspirin or Prasugrel and Aspirin as Part of a Dual Antiplatelet Therapy (DAPT) Drug Regimen
In Brief
A Phase 4 clinical trial evaluating Placebo Arm, Thienopyridine Therapy, and 1 other intervention for Coronary Artery Disease. Completed, enrolled 2,272 participants across 1 site.
Detailed Summary
EDUCATE is a prospective, multi-center study designed to collect real-world safety and clinical outcomes in subjects receiving one or more Endeavor Zotarolimus-Eluting Stents and either clopidogrel and aspirin or prasugrel and aspirin as part of a dual antiplatelet therapy (DAPT) drug regimen.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2010
Enrollment StartApr 2010
Primary CompletionApr 2014
TodayJul 2026
First PostedFeb 17, 2010
Enrollment StartApr 1, 2010
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 16.4 years ago
Interventions
Placebo Armdrug
Placebo and ASA (75 mg - 325 mg)
Thienopyridine Therapydrug
Prasugrel 5 or 10 mg or Clopidogrel 75 mg plus ASA (75 mg - 325 mg)
Surveillance Armdevice
Non randomized arm to understand clinical outcomes in a commercial setting